Clinical Trials Logo

Epoetin Alfa clinical trials

View clinical trials related to Epoetin Alfa.

Filter by:
  • None
  • Page 1

NCT ID: NCT00306267 Terminated - Cancer Clinical Trials

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of PROCRIT (Epoetin alfa) administered by injection subcutaneously (SC, under the skin), at a dose of 80,000 U once every four weeks or 40,000 U once every two in anemic patients with cancer not receiving chemotherapy or radiation therapy.